Clinical Trials Directory

Trials / Completed

CompletedNCT00671060

Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy

Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy, Inclusive, Not Accompanied by Complete Expulsion of the Contents of the Uterus

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
153 (actual)
Sponsor
Gynuity Health Projects · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

The purpose of the proposed study is to test - in a randomized, blinded trial - two different doses of the prostaglandin E1 analogue misoprostol administered buccally as a treatment for fetal death at 14 - 28 weeks, inclusive, of pregnancy. At such an advanced stage of pregnancy, the nonviable fetus is often not spontaneously evacuated, and yet timely evacuation is vital in order to avoid the possibility of, among other things, potentially life-threatening maternal coagulopathies. Current approaches to uterine evacuation in these cases include dilatation and evacuation (D\&E) surgery (in less advanced pregnancies) and labor induction with a variety of products. Misoprostol has been demonstrated to be as effective as, or more effective than, either oxytocin or prostaglandin E2 analogues for this indication in a number of small, non-FDA-approved trials which have been published in the peer-reviewed literature. In the absence of more formal study of this treatment, however, dosages are not standardized, pathways of administration vary, and other uncertainties linger. The purpose of the protocol proposed herein is to formally establish, via a randomized, double-blinded study, the safety and effectiveness of misoprostol for this indication, and to compare the value of two distinct doses, so that providers may henceforward proceed with greater authority and confidence.

Conditions

Interventions

TypeNameDescription
DRUGMisoprostol200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
DRUGMisoprostol100 mcg buccal misoprostol administered every 6 hours for upto 48 hours

Timeline

Start date
2008-10-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2008-05-02
Last updated
2013-05-08
Results posted
2013-05-06

Locations

5 sites across 2 countries: United States, Vietnam

Source: ClinicalTrials.gov record NCT00671060. Inclusion in this directory is not an endorsement.